BACKGROUND: Between January 1989 and July 1995, a prospective study of the therapeutic efficacy of the LALA 87 protocol in adult @entity981 ( @entity981 ) has been conducted. METHODS: A total of hundred and twelve @entity1 with @entity981 have been analysed. The median age of the @entity1 was 40 years (range: 15-65), the gender ratio (M/F) was 66/46, and the morphologic FAB (French-American-British) profile was L1 in 30 (26.9%) @entity1 , L2 in 71 (63.3%) and L3 morphology in 11 (9.8%) of the @entity1 . The LALA 87 protocol includes five phases: induction, consolidation, reinforcement, maintenance and central nervous system (CNS) prophylaxis with intrathecal @entity1499 and irradiation. The induction phase comprised @entity5699 50 mg/m(2) (days 1-3), @entity786 600 mg/m(2) (days 1 and 8), vincristine 1.5 mg/m(2) (on days 1, 8, 15 and 22) and daily oral @entity229 on days 1-21. Maintenance therapy was given for 2 years and consisted of different drugs as reinforcement, daily @entity4446 and weekly methotrexate. RESULTS: Complete remission (CR) was achieved in 81 (72.3%) of the @entity1 . The causes of induction failure were partial response in 10 (8.9%), and @entity204 in 12 @entity1 (10.7%), and 9 were non-responders (8.0%). Of the 81 @entity1 who achieved CR, 62 relapsed (76%). Among the relapsed @entity1 , 9 developed @entity6220 in spite of CNS prophylaxis during induction chemotherapy. Median follow-up for the living @entity1 was 110 months. Median disease-free survival (DFS) was 16 months; 19 @entity1 are still in remission with an estimated 10-year DFS (24%). Adverse prognostic factors were >50 years of age, immunologic subtype and cytogenetic profile. CONCLUSION: The results support the strategy of applying more effort and other treatment modalities in the therapy of @entity981 .

Long-term survival in XXXX in adults treated according to the LALA 87 protocol.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6220 :: ('MESH:D020279', 'Disease') :: ['CNS disease'] @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoblastic leukaemia', 'ALL'] @entity5699 :: ('MESH:D003630', 'Chemical') :: ['daunorubicin'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity4446 :: ('MESH:D015122', 'Chemical') :: ['6-mercaptopurine'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity204 :: ('MESH:D003643', 'Disease') :: ['hypoplastic death']
@entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukaemia']
